Junshi Biosciences Announces the Completion of First Patient Dosing in the Phase 3 Clinical Trial of JS207 in Combination with
JS007 for the First-Line Treatment of Advanced Hepatocellular CarcinomaSHANGHAI, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co.,
